Soleno Therapeutics Inc (SLNO) Q4 2025 Earnings Call Transcript

Why It Matters

The rapid shift to profitability and strong cash position give Soleno the runway to deepen U.S. market penetration and pursue international expansion, positioning VICAT XR as a cornerstone therapy for rare hyperphagia disorders.

Key Takeaways

• Revenue reached $190.4M in nine months of sales
• Achieved $20.9M net income, reversing prior year loss
• Cash balance topped $500M after $100M share buyback
• Active patients grew to 859, 12.5% market penetration
• EU regulatory filing on track; decision expected mid‑2026

Pulse Analysis

Soleno Therapeutics’ fourth‑quarter earnings underscore a textbook commercial launch for VICAT XR, the first FDA‑approved treatment for hyperphagia in Prader‑Willi syndrome. Within nine months, the company generated $190.4 million in revenue, achieved a $20.9 million net profit, and amassed over $500 million in cash. This financial momentum reflects disciplined cost management, a low‑cost inventory phase, and an aggressive share‑repurchase program that reinforces shareholder confidence while preserving ample liquidity for growth initiatives.

Beyond the balance sheet, Soleno’s market traction is evident in its expanding prescriber network and payer coverage. With 630 unique prescribers and 859 patients actively on therapy, the firm captured roughly 12.5% of the U.S. addressable market. Real‑world adherence remains strong, with discontinuation rates hovering around 12% for adverse events and 15% overall—figures that align with clinical trial expectations. Broad coverage across commercial, Medicaid, and Medicare plans now protects 180 million lives, facilitating rapid claim reimbursements and reinforcing the therapy’s value proposition for both patients and payers.

Looking ahead, Soleno is positioning itself for international scale and pipeline diversification. All EMA Day‑120 queries have been answered, with a Day‑180 response expected in February and a mid‑2026 decision on the EU launch. Simultaneously, the company plans an IND filing for glycogen storage disease type 1, expanding VICAT XR’s rare‑disease portfolio. A smooth CFO transition to Jennifer Volk ensures continuity in financial stewardship as Soleno leverages its robust cash reserves to fund commercialization, regulatory pursuits, and next‑generation indications, setting the stage for sustained revenue growth and market leadership.